Navigation Links
Labopharm Reports Results for Second Quarter Fiscal 2009
Date:8/7/2009

>

Research and development expenses, before research and development tax credits, for the second quarter of fiscal 2009 were $3.2 million compared with $7.0 million for the second quarter of fiscal 2008. The decrease was primarily the result of lower clinical trial costs in the second quarter of fiscal 2009. Research and development tax credits for the second quarter of fiscal 2009 were $0.3 million compared with $0.7 million for the second quarter of fiscal 2008, the result of a decrease in non-refundable Canadian federal tax credits due to a change in tax planning.

Selling, general and administrative expenses for the second quarter of fiscal 2009 were $6.3 million compared with $6.2 million for the second quarter of fiscal 2008. A significant portion of selling, general and administrative expenses for the second quarter of fiscal 2009 was the result of higher costs related to sales and marketing and the accrual for the Company's share of litigation costs incurred by Purdue Pharma to enforce certain of Purdue's U.S. patents related to Labopharm's once-daily tramadol product. These were partially offset by lower costs for consultants and professional services, a reduction in non-cash stock-based compensation and a reduction of tax on capital.

Net loss for the second quarter of fiscal 2009 was $4.9 million, or $0.09 per share, compared with $10.3 million, or $0.18 per share, for the second quarter of fiscal 2008. The decrease in net loss was primarily the result of lower research and development costs, higher gross margin on product sales and a higher foreign exchange gain, which were partially offset by lower interest income in the second quarter of fiscal 2009.

Cash, cash equivalents and marketable securities at June 30, 2009 were $27.9 million compared with $35.9 million at March 31, 2009. The cash, cash equivalents and marketable securities position at June 30, 2009 does not include the Company's Long-Term Notes, received in
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Labopharm to present at Canaccord Adams 29th Annual Global Growth Conference
2. Labopharm to host conference call Friday, August 7, 2009 at 8:30 a.m. (ET)
3. Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
4. Labopharm amends debt facility agreement with Hercules
5. Results of phase III study on Labopharms novel antidepressant published in Psychiatry (Edgemont) Journal
6. Labopharm Reports Results for First Quarter Fiscal 2009
7. Labopharm announces details for first quarter results conference call and annual meeting
8. Labopharm reports results for Phase III study on twice-daily tramadol-acetaminophen formulation
9. Labopharm to present at Cowen 29th Annual Health Care Conference
10. Labopharm Reports Results for Year End and Fourth Quarter Fiscal 2008
11. Labopharm to host conference call Thursday, February 26, 2009 at 8:30 a.m. (ET)

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2009)...tack recipient,s tissue, study finds, , ... are reporting that a genetic variation -- a missi...a bone-marrow transplant will develop a complicati...une system-related complication occurs after surge...nor does not. , When that,s the case, the immu...
(Date:11/22/2009)...an innovative healthcare benefit solutions company...ed a recapitalization with Silver Point Capital, L... Point Capital, L.P. is a private investment firm ...ation allows the Company to continue its growth an... (PRWEB) November 22, 2009 -- Health...
(Date:11/22/2009)...hine post You Tube video demonstrating the Really ... Landover, MD (PRWEB) November 22, 20...ng what a really rugged waterproof keyboard can wi...ard vs Washable Competitors Keyboard HD” vid...emium, Really Cool Keyboard from Man & Machin...
(Date:11/21/2009)...wire-USNewswire/ -- Tonight, in a partisan vote, t...version of the government takeover of health care.... this bill; like the public option, employer and i...elective abortion, which is the most onerous and m...es subsidies for private plans that cover elective...
(Date:11/21/2009)... an unprecedented expansion of federally-funded ab... preserving and protecting human life? If the bill...Yoest ,, WASHINGTON, Nov. 21 /PRNewswire-USNe...ent and CEO Dr. Charmaine Yoest responded to tonig... statement: ,, "This was a pro-abortion vote t...
Breaking Medicine News(10 mins):Health News:HealthSmart Completes Recapitalization to Support Continued Growth, Daniel D. Crowley Named Chairman 2Health News:Waterproof, Cleanable Computer Keyboard Video Comparison Now Available on You Tube 2Health News:FRC: Senate Votes to Proceed with Abortion Funding Debacle 2Health News:Leading Anti-Abortion Group Vows to Vigorously Fight the Senate Health Bill 2
...ma and John McCain arrive in Oxford, Mississippi f...reeted by AIDS activists from across the,country d...l AIDS Strategy,within his first 100 days in offic... to call attention to the thousands of people who ...
...minding,all Los Angeles residents that they have j...uter law before formal enforcement begins on Octob...l of Los Angeles approved a new,law that requires ...this ordinance into law on February 26, 2008, maki...
... Pharmacopeial (USP) Convention is pleased to anno...Material (CRM), Dextromethorphan Hydrobromide. USP...receive International Organization for Standardiza...sures improved information for measurements of the...
...s still high, although new therapeutic approaches ...ed therapy for liver fibrosis, and Authors investi...ianggan-Rongxian Soup on liver fibrosis induced by...rrhosis, and notably ameliorate the liver function...
...cal physicians for new ...International, the,pioneer of concierge medicine, ...inest primary care physicians. With 30 Fortune 500...e families that we care for are taken care of in e...
... association for professionally managed assisted l...ce of respecting the end of life choices,made by a...d CEO of the Assisted Living Federation,of America...ng which held a hearing today called Honoring Fina...
Other Medicine News:Health News:AIDS Activists from Across the Country Converge on Oxford, Mississippi, to Call on McCain and Obama to Commit to National AIDS Strategy 2Health News:New Los Angeles Spay and Neuter Law Goes Into Effect on October 1 2Health News:An effective strategy for inhibition of cirrhosis 2Health News:MD2 International Brings Highly Attentive Medicine to Chicago 2Health News:ALFA Honors End of Life Choices 2
(Date:11/20/2009)... , NEW YORK, Nov. 20 ,, ...rch report is available in its catalogue. ,, I...ts to 2015 ,, http://www.reportlinker.com/p0...-Forecasts-to-2015.html#utm_source=prnewswire&... Description ,, India Medical Equipment Market...
(Date:11/20/2009)... , NEW YORK, Nov. 20 Reportl...ort is available in its catalogue. ,, Medical ... http://www.reportlinker.com/p0164242/Medical-Ad..._source=prnewswire&utm_medium=pr&utm_campa...s and sealants is gaining preeminence in medical d...
(Date:11/20/2009)... , HOUSTON, Nov. 20 ...that Dan Moore, President and Chief Executive Offi...l present at the 21st Annual Piper Jaffray Health ... 2, 2009 at 12:00 PM EST. The conference session ...s will be presented. Piper Jaffray will host a we...
Breaking Medicine Technology:Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 2Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 3Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 4Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 5Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 6Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 7Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 8Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 9Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 10Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 11Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 12Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 13Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 2Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 3Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 4Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 5Reportlinker Adds Medical Adhesives and Sealants - A US Market Review 6Cyberonics to Present at 21st Annual Piper Jaffray Health Care Conference 2Valeritas Announces Appointment of New CEO 12391 1Valeritas Announces Appointment of New CEO 12391 2Valeritas Announces Appointment of New CEO 12391 3Researchers determine predicting factors of positive lung cancer diagnoses in chest radiographs 47488 117 million US children live more than an hour away from trauma care 47486 117 million US children live more than an hour away from trauma care 47486 2
...IRE)--May 4, 2007 - New data have,demonstrated tha...tients treated with COPAXONE(R) (glatiramer acetat...h mitoxantrone experienced a,90 percent reduction ...ase activity compared to their baseline. These ben...roughout the 24-month study,period. These long-ter...
...2007 - CeNeS Pharmaceuticals plc,(LSE: CEN), the C...e publication of an independent study in the respe... NMDA antagonist, CNS 5161. CeNeS,is developing CN...in. The independent study builds on the work that ...he study reported in ,Synapse, Dr Anat Biegon and...
Other Medicine Technology:Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 2Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 3Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 4Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 5Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 6Copaxone Treatment over Two Years after Short Term Induction with,Mitoxantrone Provided Sustained Benefits to Active,Relapsing-Remitting Multiple Sclerosis Patients 7Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 2Independent publication supports the profile of CeNeS phase II,compound, CNS 5161 3
Calcitonin RIA Kit
...s the first completely digital camera system by KA...doscopic camera systems. Digital Source Sampling t...tates the fully digital transfer of information wi...ell as loss-free data storage on all known digital...
Erbium Laser with Sapphire Erbium Handpiece for Dermatological and Cosmetic Surgery
imEXPRESS
Medicine Products: